Arcellx/$ACLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arcellx
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Ticker
$ACLX
Sector
Primary listing
Employees
209
Headquarters
Website
Arcellx Metrics
BasicAdvanced
$6.8bn
-
-$4.07
0.23
-
Price and volume
Market cap
$6.8bn
Beta
0.23
52-week high
$115.13
52-week low
$47.86
Average daily volume
1.6m
Financial strength
Current ratio
4.435
Quick ratio
4.322
Long term debt to equity
11.02
Total debt to equity
12.904
Profitability
EBITDA (TTM)
-246.405
Gross margin (TTM)
-607.22%
Net profit margin (TTM)
-1,027.25%
Operating margin (TTM)
-1,135.61%
Effective tax rate (TTM)
-0.03%
Revenue per employee (TTM)
$110,000
Management effectiveness
Return on assets (TTM)
-24.05%
Return on equity (TTM)
-53.42%
Valuation
Price to revenue (TTM)
290.674
Price to book
16.57
Price to tangible book (TTM)
16.57
Price to free cash flow (TTM)
-30.472
Free cash flow yield (TTM)
-3.28%
Free cash flow per share (TTM)
-3.776
Growth
Revenue change (TTM)
-79.35%
Earnings per share change (TTM)
102.89%
3-year earnings per share growth (CAGR)
-7.81%
Arcellx News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs